CoImmune Archives | Be Korea-savvy

Home / Posts tagged CoImmune

CoImmune Announces Positive Results from Phase 1/2 Clinical Trial of Allogeneic CAR-CIK Cells in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia

DURHAM, N.C., Dec. 15 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that results from a Phase 1/2 clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company’s chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform, demonstrated sustained [...]

CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.

DURHAM, N.C., Nov. 17 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, announced a research collaboration with Yeda Research and Development Company Ltd. (Yeda), the commercial arm of the Weizmann Institute of Science, to evaluate the applications of the Synthetic Immune Niche (SIN) technology, [...]

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

DURHAM, N.C., Nov. 15 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company’s board of directors. “As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and [...]

CoImmune Announces Collaboration with Top U.S. Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors

DURHAM, N.C., Oct. 18 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced a license and collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors. Under the terms [...]

CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

DURHAM, N.C., Sept. 20 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech [...]

CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

DURHAM, N.C., July 6 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital [...]

CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors

DURHAM, N.C., Feb. 24 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors. Dr. Baracchini brings a wealth of biotechnology industry and financial expertise, as well [...]

Chimeric Antigen Receptor (CAR)-modified Cytokine Induced Killer Cell (CAR-CIK) Technology Featured at ASH

DURHAM, N.C., Dec. 16 (Korea Bizwire) — CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy [...]

CoImmune, Inc. Announces Closing of $45 Million Series A Financing

DURHAM, N.C., Nov. 10 (Korea Bizwire) — CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the closing of a $45M Series A financing. CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, [...]

CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.

DURHAM, N.C. , April 30 (Korea Bizwire) — CoImmune, Inc. today announced that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic immuno-oncology platforms. Formula Pharmaceuticals merged into CoImmune with CoImmune as the surviving company. CoImmune will continue to focus on running a Phase 2b trial for lead asset, CMN-001, [...]